Showing 1 to 1 of 1 results
napoli.repubblica.it
🌐 85% Global Worthiness
Oncolytic Virus Immunotherapy Shows Promise for Advanced Melanoma
In a phase 2 clinical trial, combining the oncolytic virus immunotherapy RP1 with nivolumab resulted in a 30% overall response rate and 15% complete response rate in 140 patients with advanced melanoma unresponsive to prior immunotherapy, leading to FDA Breakthrough Therapy designation.
Oncolytic Virus Immunotherapy Shows Promise for Advanced Melanoma
In a phase 2 clinical trial, combining the oncolytic virus immunotherapy RP1 with nivolumab resulted in a 30% overall response rate and 15% complete response rate in 140 patients with advanced melanoma unresponsive to prior immunotherapy, leading to FDA Breakthrough Therapy designation.
Progress
48% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results